Clinical Efficacy and Safety of Fluvoxamine in COVID-19 Patients: An Umbrella Review of Systematic Reviews and Meta-Analyses

Introduction: Fluvoxamine is an agonist for the sigma-1 receptor, through which it controls inflammation. It helps reduce the cytokine storm associated with the COVID-19 virus by regulating the production of IL-6 and gene expression. This review of systematic reviews (SRs) aims to summarize the eff...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Omar Irfan, Muhammad Jansher, Wania Moeen, Muhammad Sohaib Khan, Muhammad Bin Hammad, Rubaid Dhillon, Nabira Khan, Abia Abdullah, Mohammad Aadil Qamar, Ayesha Rashid, Javaid Ahmed Khan, Ali Bin Sarwar Zubairi
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	American Society for Inclusion, Diversity, and Equity in Healthcare (ASIDE) 2025-07-01
סדרה:	ASIDE Internal Medicine
נושאים:	Fluvoxamine COVID-19 Cytokine storm IL-6 Hospitalization Disease progression
גישה מקוונת:	https://asidejournals.com/index.php/internal-medicine/article/view/86
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!